CN106459221B - 单链trail受体激动剂蛋白 - Google Patents

单链trail受体激动剂蛋白 Download PDF

Info

Publication number: CN106459221B
Authority: CN; China
Prior art keywords: ser; gly; leu; lys; glu
Prior art date: 2014-04-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CN201580031858.7A

Other languages

English (en)

Chinese (zh)

Other versions

CN106459221A (zh

Inventor

O.希尔

C.吉菲尔斯

M.蒂曼

F.G.布查南

D.C.菲利普斯

S.E.拉普

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Apogenix AG

AbbVie Inc

Original Assignee

Apogenix AG

AbbVie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-23

Filing date

2015-04-23

Publication date

2020-09-01

2015-04-23 Application filed by Apogenix AG, AbbVie Inc filed Critical Apogenix AG

2015-04-23 Priority to CN202010767219.XA priority Critical patent/CN111718424A/zh

2017-02-22 Publication of CN106459221A publication Critical patent/CN106459221A/zh

2020-09-01 Application granted granted Critical

2020-09-01 Publication of CN106459221B publication Critical patent/CN106459221B/zh

Status Expired - Fee Related legal-status Critical Current

2035-04-23 Anticipated expiration legal-status Critical

Links

0 CC(C)CCC1C(C)C*(CC(O)=O)C*(C*CC*CCCC(C)CC(O)=O)CC(CN)CC1 Chemical compound CC(C)CCC1C(C)C*(CC(O)=O)C*(C*CC*CCCC(C)CC(O)=O)CC(CN)CC1 0.000 description 2

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)

CN201580031858.7A 2014-04-23 2015-04-23 单链trail受体激动剂蛋白 Expired - Fee Related CN106459221B (zh)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CN202010767219.XA CN111718424A (zh)	2014-04-23	2015-04-23	单链trail受体激动剂蛋白

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461983152P	2014-04-23	2014-04-23
US61/983152		2014-04-23
PCT/US2015/027270 WO2015164588A1 (en)	2014-04-23	2015-04-23	Single-chain trail-receptor agonist proteins

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CN202010767219.XA Division CN111718424A (zh)	2014-04-23	2015-04-23	单链trail受体激动剂蛋白

Publications (2)

Publication Number	Publication Date
CN106459221A CN106459221A (zh)	2017-02-22
CN106459221B true CN106459221B (zh)	2020-09-01

Family

ID=53055121

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201580031858.7A Expired - Fee Related CN106459221B (zh)	2014-04-23	2015-04-23	单链trail受体激动剂蛋白
CN202010767219.XA Pending CN111718424A (zh)	2014-04-23	2015-04-23	单链trail受体激动剂蛋白

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN202010767219.XA Pending CN111718424A (zh)	2014-04-23	2015-04-23	单链trail受体激动剂蛋白

Country Status (38)

Country	Link
US (5)	US9908927B2 (2)
EP (2)	EP3366699A1 (2)
JP (2)	JP6523331B2 (2)
KR (2)	KR20190135546A (2)
CN (2)	CN106459221B (2)
AR (1)	AR100168A1 (2)
AU (3)	AU2015249649B2 (2)
BR (1)	BR112016024515B1 (2)
CA (2)	CA2946402C (2)
CL (1)	CL2016002683A1 (2)
CR (1)	CR20160516A (2)
CY (1)	CY1120281T1 (2)
DK (1)	DK3134430T3 (2)
DO (1)	DOP2016000284A (2)
EC (1)	ECSP16089579A (2)
ES (1)	ES2672368T3 (2)
HR (1)	HRP20180950T1 (2)
HU (1)	HUE038914T2 (2)
IL (2)	IL248244B (2)
LT (1)	LT3134430T (2)
MA (2)	MA39770A (2)
MX (2)	MX2016013858A (2)
MY (1)	MY181986A (2)
NO (1)	NO2776305T3 (2)
PE (1)	PE20170299A1 (2)
PH (2)	PH12020500377A1 (2)
PL (1)	PL3134430T3 (2)
PT (1)	PT3134430T (2)
RS (1)	RS57153B1 (2)
RU (1)	RU2699285C2 (2)
SG (3)	SG10202111785VA (2)
SI (1)	SI3134430T1 (2)
SM (1)	SMT201800286T1 (2)
TR (1)	TR201806912T4 (2)
TW (2)	TWI747178B (2)
UA (1)	UA118286C2 (2)
UY (1)	UY36095A (2)
WO (1)	WO2015164588A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2754432T3 (es) *	2015-05-04	2020-04-17	Apogenix Ag	Proteínas agonistas de receptor CD40 de cadena sencilla
CA3002741A1 (en) *	2015-10-23	2017-04-27	Apogenix Ag	Single-chain gitr-receptor agonist proteins
CA3002587A1 (en) *	2015-10-23	2017-04-27	Apogenix Ag	Single-chain light receptor agonist proteins
EP3364995B1 (en)	2015-10-23	2021-08-04	Apogenix AG	Single-chain cd27-receptor agonist proteins
WO2017102010A1 (en) *	2015-12-17	2017-06-22	Biontech Rna Pharmaceuticals Gmbh	Novel cytokine fusion proteins
CA3054286A1 (en)	2016-03-01	2017-09-08	The Board Of Trustees Of The University Of Illinois	L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
AU2017234679A1 (en) *	2016-03-16	2018-08-30	Merrimack Pharmaceuticals, Inc.	Engineered trail for cancer therapy
US10501744B2 (en)	2016-05-04	2019-12-10	Indiana University Research And Technology Corporation	Presentation of bioactive proteins
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP2019517570A (ja) *	2016-06-13	2019-06-24	メリマックファーマシューティカルズインコーポレーティッド	Ｔｒａｉｌベースの治療剤または細胞死受容体アゴニストを用いて患者を選択および治療する方法
EP3360898A1 (en)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
JP7744621B2 (ja) *	2017-08-11	2025-09-26	ザボードオブトラスティーズオブザユニヴァーシティオブイリノイ	切断されたモルモットｌ－アスパラギナーゼバリアントおよび使用の方法
TW202002952A (zh)	2018-03-15	2020-01-16	美商艾伯維有限公司	用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019178438A1 (en)	2018-03-15	2019-09-19	Abbvie Inc.	Abbv-621 in combination with anti-cancer agents for the treatment of cancer
EP4149964A2 (en)	2020-05-15	2023-03-22	Apogenix AG	Multi-specific immune modulators
AU2022281108A1 (en)	2021-05-28	2023-12-14	Julius-Maximilians-Universität Würzburg	Recombinant proteinaceous binding molecules
WO2023088876A1 (en)	2021-11-16	2023-05-25	Apogenix Ag	Multi-specific immune modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010010051A1 (en) *	2008-07-21	2010-01-28	Apogenix Gmbh	Tnfsf single chain molecules
CN102369291A (zh) *	2009-01-23	2012-03-07	比奥根艾迪克Ma公司	效应子功能降低的稳定Fc多肽及使用方法
WO2013092983A2 (en) *	2011-12-23	2013-06-27	Innate Pharma	Enzymatic conjugation of polypeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001025277A1 (en)	1999-10-07	2001-04-12	Maxygen Aps	Single-chain antagonist polypeptides
DE19963859A1 (de)	1999-12-30	2001-07-12	Apotech Res & Dev Ltd	Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en)	2000-07-21	2002-01-21	Robert Simoneau	C-chip
IL155812A0 (en) *	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
WO2003091447A2 (en) *	2002-04-26	2003-11-06	California Institute Of Technology	D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de)	2004-03-26	2005-10-20	Univ Stuttgart	Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) *	2005-02-18	2006-08-24	Genentech, Inc.	Methods of using death receptor agonists and EGFR inhibitors
CN101160323A (zh) *	2005-04-15	2008-04-09	拉帕波特家族医学科学研究所	用于治疗mcp-1/ccr2相关疾病的分子及其使用方法
US8008443B2 (en)	2005-04-26	2011-08-30	Medimmune, Llc	Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en)	2006-08-28	2008-03-05	Apogenix GmbH	TNF superfamily fusion proteins
ES2560871T3 (es)	2007-07-10	2016-02-23	Apogenix Gmbh	Proteínas de fusión de colectina de la superfamilia de TNF
CA2726087A1 (en)	2008-06-03	2009-12-10	Tariq Ghayur	Dual variable domain immunoglobulins and uses thereof
WO2010033315A1 (en)	2008-09-22	2010-03-25	Amgen Inc.	Method of treatment
JP2012504969A (ja) *	2008-10-10	2012-03-01	アナフォアインコーポレイテッド	Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
US8664366B2 (en)	2009-01-09	2014-03-04	Apogenix Gmbh	Fusion proteins forming trimers
BR112012017164A2 (pt)	2009-12-22	2019-09-24	Novartis Ag	proteína de fusão de região constante de anticorpo-cd47 tetravalente
WO2011130324A1 (en) *	2010-04-13	2011-10-20	Medimmune, Llc	Fibronectin type iii domain-based multimeric scaffolds
EP3409686B1 (en) *	2012-07-18	2022-04-13	Apogenix AG	Composition comprising a mixture of cd95-fc isoforms

2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
2015
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en not_active Ceased
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010010051A1 (en) *	2008-07-21	2010-01-28	Apogenix Gmbh	Tnfsf single chain molecules
CN102369291A (zh) *	2009-01-23	2012-03-07	比奥根艾迪克Ma公司	效应子功能降低的稳定Fc多肽及使用方法
WO2013092983A2 (en) *	2011-12-23	2013-06-27	Innate Pharma	Enzymatic conjugation of polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Effi cacy Independent of Cross-Linking via Fc g Receptors;Christian Gieffers 等;《Molecular Cancer Therapeutics》;20131007;第12卷(第12期);第2735-2748页 *
Death receptor agonist therapies for cancer, which is the right TRAIL?;Pamela M. Holland;《Cytokine & Growth Factor Reviews》;20131224;第25卷(第2期);第185-193页 *
Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity;Haizhen Wang 等;《Molecular Cancer Therapeutics》;20140115;第13卷(第3期);第643-651页 *

Also Published As

Publication number	Publication date
US20150337027A1 (en)	2015-11-26
US9908927B2 (en)	2018-03-06
US20180222962A1 (en)	2018-08-09
PH12016502079A1 (en)	2016-12-19
ECSP16089579A (es)	2018-05-31
KR20170012257A (ko)	2017-02-02
TWI683825B (zh)	2020-02-01
SMT201800286T1 (it)	2018-07-17
BR112016024515A2 (pt)	2017-10-10
CA3184067A1 (en)	2015-10-29
CN106459221A (zh)	2017-02-22
TR201806912T4 (tr)	2018-06-21
CR20160516A (es)	2017-05-10
EP3134430B1 (en)	2018-03-21
IL248244A0 (en)	2016-11-30
SG10201806465TA (en)	2018-08-30
CY1120281T1 (el)	2019-07-10
KR20190135546A (ko)	2019-12-06
TWI747178B (zh)	2021-11-21
JP6714751B2 (ja)	2020-06-24
EP3366699A1 (en)	2018-08-29
HRP20180950T1 (hr)	2018-08-10
CA2946402C (en)	2023-02-28
SG10202111785VA (en)	2021-12-30
MX2016013858A (es)	2017-08-02
MA39770A (fr)	2015-10-29
NO2776305T3 (2)	2018-01-27
PH12020500377A1 (en)	2022-11-14
MA45069A (fr)	2019-04-03
LT3134430T (lt)	2018-05-10
SI3134430T1 (en)	2018-05-31
IL248244B (en)	2020-03-31
AU2015249649B2 (en)	2018-10-04
WO2015164588A1 (en)	2015-10-29
PH12016502079B1 (en)	2016-12-19
PT3134430T (pt)	2018-04-20
DOP2016000284A (es)	2017-02-15
AU2018271369A1 (en)	2018-12-20
BR112016024515B1 (pt)	2020-03-31
RU2016145608A3 (2)	2018-12-26
AU2015249649A1 (en)	2016-11-10
SG11201608767XA (en)	2016-11-29
PE20170299A1 (es)	2017-05-06
UY36095A (es)	2015-10-30
JP2019162114A (ja)	2019-09-26
TW202024123A (zh)	2020-07-01
ES2672368T3 (es)	2018-06-14
RU2016145608A (ru)	2018-05-28
AR100168A1 (es)	2016-09-14
EP3134430A1 (en)	2017-03-01
RU2699285C2 (ru)	2019-09-04
TW201620928A (zh)	2016-06-16
US20250145688A1 (en)	2025-05-08
AU2020202247A1 (en)	2020-04-23
IL272612A (en)	2020-03-31
CL2016002683A1 (es)	2017-07-07
PL3134430T3 (pl)	2018-08-31
US20210040178A1 (en)	2021-02-11
KR102079919B1 (ko)	2020-02-24
MX2019013587A (es)	2020-01-13
MY181986A (en)	2021-01-18
UA118286C2 (uk)	2018-12-26
RS57153B1 (sr)	2018-07-31
NZ725476A (en)	2023-09-29
JP6523331B2 (ja)	2019-05-29
DK3134430T3 (en)	2018-05-22
CA2946402A1 (en)	2015-10-29
AU2018271369B2 (en)	2020-01-02
CN111718424A (zh)	2020-09-29
US20240174731A1 (en)	2024-05-30
JP2017513503A (ja)	2017-06-01
HUE038914T2 (hu)	2018-12-28

Legal Events

Date	Code	Title	Description
2017-02-22	C06	Publication
2017-02-22	PB01	Publication
2017-05-17	SE01	Entry into force of request for substantive examination
2017-05-17	SE01	Entry into force of request for substantive examination
2020-09-01	GR01	Patent grant
2020-09-01	GR01	Patent grant
2025-04-25	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20200901
2025-04-25	CF01	Termination of patent right due to non-payment of annual fee

Publication	Publication Date	Title
US20250145688A1 (en)	2025-05-08	Single-chain trail-receptor agonist proteins
US10793616B2 (en)	2020-10-06	Single-chain CD40-receptor agonist proteins
US20210246190A1 (en)	2021-08-12	Single-chain cd137-receptor agonist proteins
US10683332B2 (en)	2020-06-16	Single-chain light receptor agonist proteins
AU2016341402B2 (en)	2020-08-27	Single-chain GITR-receptor agonist proteins
HK1260151A1 (en)	2019-12-13	Single-chain trail-receptor agonist proteins
HK1235072B (en)	2018-08-24	Single-chain trail-receptor agonist proteins
HK1235072A1 (en)	2018-03-02	Single-chain trail-receptor agonist proteins
NZ725476B2 (en)	2024-01-04	Single-chain trail-receptor agonist proteins